Novo Nordisk Plans Denecimib U.S. Launch In H1 2027

Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) informed the company that its Biologics License Application (BLA) review of denecimig for haemophilia A treatment remains ongoing, with no new regulatory timeline communicated.